Welcome to Edition 8.04 of the Rocket Report! The Pentagon's Golden Dome missile defense shield will be a lot of things. Along with new sensors, command and control systems, and satellites, Golden Dome will require a lot of rockets. The pieces of the Golden Dome architecture operating in orbit will ride to space on commercial launch vehicles. And Golden Dome's space-based interceptors will essentially be designed as flying fuel tanks with rocket engines. This shouldn't be overlooked, and that's why we include a couple of entries discussing Golden Dome in this week's Rocket Report.
As always, we welcome reader submissions. If you don't want to miss an issue, please subscribe using the box below (the form will not appear on AMP-enabled versions of the site). Each report will include information on small-, medium-, and heavy-lift rockets, as well as a quick look ahead at the next three launches on the calendar.
Space-based interceptors are a real challenge. The newly installed head of the Pentagon's Golden Dome missile defense shield knows the clock is ticking to show President Donald Trump some results before the end of his term in the White House, Ars reports. Gen. Michael Guetlein identified command-and-control and the development of space-based interceptors as two of the most pressing technical challenges for Golden Dome. He believes the command-and-control problem can be "overcome in pretty short order." The space-based interceptor piece of the architecture is a different story.
Not surprisingly, Congress is pushing back against the Trump administration's proposal to cancel the Space Launch System, the behemoth rocket NASA has developed to propel astronauts back to the Moon.
Spending bills making their way through both houses of Congress reject the White House's plan to wind down the SLS rocket after two more launches, but the text of a draft budget recently released by the House Appropriations Committee suggests an openness to making some major changes to the program.
The next SLS flight, called Artemis II, is scheduled to lift off early next year to send a crew of four astronauts around the far side of the Moon. Artemis III will follow a few years later on a mission to attempt a crew lunar landing at the Moon's south pole. These missions follow Artemis I, a successful unpiloted test flight in 2022.
A budget-writing panel in the House of Representatives passed a $24.8 billion NASA budget bill Tuesday, joining a similar subcommittee in the Senate in maintaining the space agency's funding after the White House proposed a nearly 25 percent cut.
The budget bills making their way through the House and Senate don't specify funding levels for individual programs, but the topline numbers—$24.8 billion in the House version and $24.9 billion the Senate bill—represent welcome news for scientists, industry, and space enthusiasts bracing for severe cuts requested by the Trump administration.
The spending plan passed Tuesday by the House Appropriations Committee's Subcommittee on Commerce, Justice, Science, and Related Agencies covers NASA and numerous other federal agencies. The $24.8 billion budget the House seeks for NASA is $6 billion more than the Trump administration's budget proposal, and keeps NASA's funding next year the same as this year.
NASA's New Horizons spacecraft got a fleeting glimpse of Pluto 10 years ago, revealing a distant world with a picturesque landscape that, paradoxically, appears to be refreshing itself in the cold depths of our Solar System.
The mission answered numerous questions about Pluto that have lingered since its discovery by astronomer Clyde Tombaugh in 1930. As is often the case with planetary exploration, the results from New Horizons' flyby of Pluto on July 14, 2015, posed countless more questions. First and foremost, how did such a dynamic world come to be so far from the Sun?
For at least the next few decades, the only resources available for scientists to try to answer these questions will be either the New Horizons mission's archive of more than 50 gigabits of data recorded during the flyby, or observations from billions of miles away with powerful telescopes on the ground or space-based observatories like Hubble and James Webb.
Recruiter Jaylyn Jones received a 16% score when she ran the résumé that landed her over 12 job interviews within three months through an online résumé scanner that ranks how strong a résumé is.
fizkes/Getty Images
Jaylyn Jones landed over 12 interviews without tailoring her résumé for ATS scanners.
Jones, a recruiter, emphasizes showcasing job competence over keyword stuffing in résumés.
She shared which advice she found least helpful when she submitted her résumé through the scanner.
This as-told-to essay is based on a conversation with Jaylyn Jones, a 32-year-old recruiter based in Pittsburgh. It's been edited for length and clarity.
One of the biggest job-seeking myths I've heard is that aggressive Applicant Tracking System (ATS) scanners will filter out applicants whose applications are formatted a specific way. That's just not the case.
I've been a recruiter for three years, and about a year ago, I started hunting for a new role. When I was applying for new recruiting jobs in 2024, I took my personal experience using ATS systems into account and proved that I didn't need to tailor my résumé for ATS scanners to land a position.
Here's how I formatted my résumé to stand out among the rest.
I've used ATS scanners to recruit people for jobs
My first recruiting job was at JP Morgan from 2021 to 2024, in which I used Greenhouse, a popular ATS system, to help streamline the recruiting process.
Greenhouse rejected or flagged candidates based on straightforward questions like "Are you over the age of 18?" and "Are you authorized to work in the US?" However, no applicants were filtered out by keywords or formatting. If 1,000 people applied, I saw 1,000 applications.
I could manually search for keywords if I wanted to look for someone with specific experience, but that didn't get rid of applications that lacked that keyword.
On my résumé, I focused less on keywords and more on showing my ability to do the job
I went bullet-by-bullet on every job description and made sure there was something on my résumé that showed my competence in that area.
When reviewing my résumé, I'd simply ask myself, "Would a reasonable person look at what I have on my résumé and say, "Yes, they can do this job?" My strategy worked; I got interviewed by over 12 companies, and I got hired to recruit at a tech company in less than three months.
In my current role, I receive a lot of résumés that are filled with a page worth of keyword fodder before getting to actual experience. Once it reaches the experience section, that part is just as filled with buzzwords. When I see a résumé like this, it's not a red flag. I see it as somebody who has not been given the information and tools to be successful.
Jobscan gave my résumé a failing score
Recently, I plugged the résumé that landed me my most recent job into Jobscan, an online résumé scanner that ranks how strong a résumé is, just to see what the platform would say.
The biggest critique I received was that I was missing keywords. For example, the scanner said something like "the job description says the word "recruiting" 13 times, but your résumé only says it twice." Then it prompted me to add the keyword more times.
It was also very particular about language, such as bumping my score down for saying I was a "campus recruiter" at JP Morgan instead of a "university recruiter." It gave my résumé a 16% score.
As a recruiter, I honestly didn't see any tips from the résumé scanner that would be useful for a job seeker. If anything, it can be harmful to an applicant's success if they're more caught up in using the word "evaluate" than actually citing their experience evaluating.
My biggest tip is to focus on providing evidence over keywords
So many job seekers are having such a difficult time in this market, and they're doing everything they can possibly think of to be more successful, but if you're going to use AI, don't be sloppy.
A common ChatGPT prompt that job seekers might use is "Tailor my résumé to this job." AI often responds to this by shoehorning keywords from the job description into haphazard bullet points. Using keywords isn't helpful without proper context.
I prefer uploading the job description and using the prompt "analyze my résumé for any gaps in skills or qualifications based on this job description, and make suggestions about what to change." This might cue you to add any missing skills that the job post is looking for.
The right prompt allows job seekers to own their experience, not just blindly trust ChatGPT. This helped me during my job search.
Editor's note — A representative from Jobscan sent the following comment to BI : "A Jobscan Match Rate isn't a grade on your career; it's a risk assessment against a frustrating system. A low score doesn't mean you're unqualified; it means you're at high risk of being invisible to the automated or manual filters that 88% of employers admit will vet out good candidates. Based on third-party research and our own surveys and conversations with job seekers and recruiters, Jaylyn's job search experience is certainly an exception to the rule."
If you are professional with helpful résumé tips you'd like to share, please email the editor, Manseen Logan, at [email protected].
NASA's Space Launch System appears to have a finite shelf life. The Trump administration wants to cancel it after just three launches, while the preliminary text of a bill making its way through Congress would extend it to five flights.
But chances are low the Space Launch System will make it to nine flights, and if it does, it's questionable that it would reach that point before 2040. The SLS rocket is a core piece of NASA's plan to return US astronauts to the Moon under the Artemis program, but the White House seeks to cancel the program in favor of cheaper commercial alternatives.
For the second time in less than a week, NASA test-fired new propulsion hardware Thursday that the agency would need to keep SLS alive. Last Friday, a new liquid-fueled RS-25 engine ignited on a test stand at NASA's Stennis Space Center in Mississippi. The hydrogen-fueled engine is the first of its kind to be manufactured since the end of the Space Shuttle program. This particular RS-25 engine is assigned to power the fifth flight of the SLS rocket, a mission known as Artemis V.
Shares of Tempus AI (NASDAQ: TEM) are falling on Wednesday. One of Cathie Wood's largest holdings, the company's stock plummeted 18.7% as of 2:15 p.m. ET. The collapse comes as the S&P 500(SNPINDEX: ^GSPC) and the Nasdaq Composite(NASDAQINDEX: ^IXIC) were mostly flat.
Tempus, a "precision medicine" company that leverages artificial intelligence (AI) to better treat patients, was the target of a short report from short-seller Spruce Point Capital Management that alleges the stock has as much as a 60% downside.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Tempus faces significant allegations
The report, released as the market opened today, outlines Spruce's allegations. The most damning of these include a history of company leadership, especially founder Eric Lefkofsky, creating advanced technology companies that make bold claims they often fail to back up. The report says that the leadership exits the companies, having made millions, early, leaving shareholders with losses or "lackluster" returns.
The report also alleges that Lefkofsky and Tempus leadership are misleading the public as to their use of AI. The report states that just before the company IPO'd, as AI hype was peaking, the company rebranded from Tempus Labs to Tempus AI. Despite its centrality in the company's new name, branding, and public statements, only 2% of its 2024 revenue came from AI applications. The report alleges that Tempus' actual ability to utilize AI is vastly overstated.
Image source: Getty Images.
There is reason to be skeptical
While there are many more allegations -- like accounting irregularities and weakening relationships with core customers like AstraZeneca -- it's important to take it with a grain of salt. The short-seller has a financial stake in seeing Tempus' stock price decline. Still, the report is convincing, and even if most of the allegations prove untrue, I agree with its final assessment that the stock is already overpriced. I would stay away from Tempus, even if it is one of Cathie Wood's favorites.
Should you invest $1,000 in Tempus Ai right now?
Before you buy stock in Tempus Ai, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $653,389!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $830,492!*
Now, it’s worth notingStock Advisor’s total average return is982% — a market-crushing outperformance compared to171%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor.
Shares of artificial intelligence (AI) company Tempus AI(NASDAQ: TEM) are down to the tune of 15.6% as of 11:13 a.m. ET on Wednesday, upended by a warning from investment management outfit Spruce Point Capital Management.
Just consider the source, and the fact that Spruce Point has something to gain by Tempus AI stock's pullback.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Why the name seems familiar
If the name rings a bell, it may be because California Representative Nancy Pelosi disclosed a bullish stake in the company in January of this year, just months after its June 2024 initial public offering. The company's AI-powered platform helps pharmaceutical developers optimize the creation, testing, and commercialization of new drugs, saving time and money.
The potential for such a tool is obvious, as is the reason for Pelosi's interest. Indeed, analysts expect revenue growth of nearly 80% this year and 25% next year, en route to a projected swing to profitability in 2027.
Not every observer is impressed, though, or even convinced. Spruce Point Capital Management publicly cautioned all investors on Wednesday that "Tempus Founder Eric Lefkofsky and his associates have a history of promoting disruptive technology companies, cashing out early, and leaving public shareholders with losses or lackluster returns." All told, Spruce believes Tempus AI stock's value is 50% to 60% below its price prior to Wednesday's plunge.
To be fair, there's some validity to Spruce Point's concerns.
But keep them in perspective. Spruce Point Capital Management and its clients have short positions in Tempus AI stock, meaning they benefit if this ticker loses value. Also bear in mind that one of Spruce's acknowledged focuses is short-selling. In other words, the firm regularly makes such bearish cases for companies, then profits when they decline.
Not a new reason to steer clear
Again, it's not that Spruce's points are incorrect, or that its conclusions are unreasonable. Much of the risk voiced today was already known and accepted, though, and built into this volatile stock's price. Risk is the norm for stocks of this ilk.
That said, it's worth noting that well-established pharmaceutical companyAstraZeneca, Henry Ford Health, and the Mayo Clinic, as well as several universities and research hospitals, are using Tempus AI's technology. Although not all of these partnerships and collaboration efforts will necessarily translate into profitable revenue, the caliber and sheer quantity of organizations interested in Tempus AI's capabilities speak volumes.
Bottom line? There's plenty of risk here, to be sure. But there's no new or additional risk being injected by Spruce Point's warning. If you were willing to take this risk yesterday, nothing's actually changed in the meantime except the stock's price.
Should you invest $1,000 in Tempus Ai right now?
Before you buy stock in Tempus Ai, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $653,389!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $830,492!*
Now, it’s worth notingStock Advisor’s total average return is982% — a market-crushing outperformance compared to171%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor.
Since 2017, a particularly dangerous strain of E. coli O157:H7 has emerged across the country to spark outbreaks, severe disease, and deaths. It spreads in various ways: via leafy greens and contaminated beef, like its relatives, but also recreational waters. Hundreds of people across 46 states have been infected, and health officials have documented at least nine separate outbreaks. One in 2018, linked to lettuce, caused over 200 infections across 37 states, killing five people and causing a severe kidney condition in 26.
Now, a sweeping genetic analysis by researchers at the Centers for Disease Control and Prevention suggests a tiny mutation in one of the bacteria's molecular weapons may be behind the strain's rise. The finding, published recently in the journal Emerging Infectious Diseases, provides insights into this clinically significant plague and its rise to prominence. It also highlights the role of the bacteria's sophisticated military tactics.
The mutated weapon is part of a complex system that E. coli and other harmful bacteria sometimes use called a Type 3 Secretion System (T3SS). This involves molecular machinery that basically functions like a syringe, complete with a long needle that is poked into the cells of its victims. The T3SS then directly injects a fleet of hostile proteins. Those proteins—called effectors—attack specific targets that collectively disable the host's defense responses and make the host more hospitable for its bacterial conqueror.
Welcome to Edition 7.43 of the Rocket Report! There's been a lot of recent news in hypersonic testing. We cover some of that in this week's newsletter, but it's just a taste of the US military's appetite for fielding its own hypersonic weapons, and conversely, the Pentagon's emphasis on the detection and destruction of an enemy's hypersonic missiles. China has already declared its first hypersonic weapons operational, and Russia claims to have them, too. Now, the Pentagon is finally close to placing hypersonic missiles with combat units. Many US rocket companies believe the hypersonics sector is a lucrative business. Some companies have enough confidence in this emerging market—or lack of faith in the traditional space launch market—to pivot entirely toward hypersonics. I'm interested in seeing if their bets pay off.
As always, we welcome reader submissions. If you don't want to miss an issue, please subscribe using the box below (the form will not appear on AMP-enabled versions of the site). Each report will include information on small-, medium-, and heavy-lift rockets, as well as a quick look ahead at the next three launches on the calendar.
Stratolaunch tests reusable hypersonic rocket plane. Stratolaunch has finally found a use for the world's largest airplane. Twice in the last five months, the company launched a hypersonic vehicle over the Pacific Ocean, accelerated it to more than five times the speed of sound, and autonomously landed at Vandenberg Space Force Base in California, Ars reports. Stratolaunch used the same Talon-A vehicle for both flights, demonstrating its reusability, a characteristic that sets it apart from competitors. Zachary Krevor, Stratolaunch's president and CEO, said his team aims to ramp up to monthly flights by the end of the year.
Amid a bullish backdrop for the broader market, Tempus AI(NASDAQ: TEM) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m. ET. At the same point in time, the S&P 500 was up 2.1%, and the Nasdaq Composite had risen 2.8%.
Investors are having a strong positive reaction to news that the Trump administration is apparently interested in getting a trade deal done with China and lowering tariffs in the not-too-distant future. In addition to buying momentum that's lifting valuations across the broader market, Tempus AI stock is climbing thanks to news that the company has formed a new partnership with AstraZeneca and Pathos AI. The team-up will see the trio of companies working to build an artificial intelligence (AI) model for oncology that can help generate clinical insights, aid in the discovery of new drug targets, and help develop treatments.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Is Tempus AI stock a buy right now?
Against the backdrop of an 8% decline for the S&P 500, Tempus AI has managed to rocket 48% higher across 2025's trading. As an early, specialized leader in healthcare AI software, the company has plenty of long-term promise -- but its valuation profile also comes with significant risk.
The company's revenue increased 30.4% annually last year to reach $693.4 million, and its 55% gross margin in the period looks promising for a business that could still be in very early scaling stages. On the other hand, the company seemingly has a long way to go before shifting into profitability and recorded a net loss of $705.8 million last year. With a market cap of roughly $8.7 billion, Tempus AI is valued at approximately 12.6 times last year's sales.
The business has huge expansion potential and will likely continue to serve up very strong revenue growth this year, but its heavily forward-looking valuation suggests the stock is probably only a good fit for investors with high risk tolerance. If you're interested in building a position in this AI healthcare software pure play, I would recommend dollar-cost averaging into the stock due to the potential for macroeconomic and geopolitical developments to spur continued volatility for the market in the near term.
Should you invest $1,000 in Tempus Ai right now?
Before you buy stock in Tempus Ai, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $561,046!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $606,106!*
Now, it’s worth notingStock Advisor’s total average return is811% — a market-crushing outperformance compared to153%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor.
Shares of Tempus AI(NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear partnership with AstraZeneca and Pathos AI to build a multimodal foundation model for cancer drug discovery and development.
Tempus AI has invested heavily over the last decade to create one of the world's largest libraries of multimodal data that can be used in developing precision medicines. The company's de-identified oncology data will be critical in building the foundation model that AstraZeneca hopes to use to accelerate its development of new cancer drugs and increase the chances of success in clinical testing for its candidates.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
What this deal means for Tempus AI
Tempus AI will receive $200 million in data licensing and model development fees from AstraZeneca. This amount almost exactly matches the amount of revenue the company generated in the fourth quarter of 2024.
The healthcare AI company will also be able to use the multimodal foundation model it's building in collaboration with AstraZeneca and Pathos AI in its own efforts to improve patient care. This could bode well for Tempus AI's appeal to other big drugmakers seeking to harness the power of AI in their drug development processes.
Is Tempus AI stock a smart pick to buy now?
Risk-averse investors probably should look to other stocks to buy instead of Tempus AI. The company continues to lose money and is difficult to value. However, I think Tempus AI could be a smart pick for aggressive growth investors to buy and hold. The deal with AstraZeneca underscores the promise of its AI platform and data.
Should you invest $1,000 in Tempus Ai right now?
Before you buy stock in Tempus Ai, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $561,046!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $606,106!*
Now, it’s worth notingStock Advisor’s total average return is811% — a market-crushing outperformance compared to153%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor.
Welcome to Edition 7.39 of the Rocket Report! Not getting your launch fix? Buckle up. We're on the cusp of a boom in rocket launches as three new megaconstellations have either just begun or will soon begin deploying thousands of satellites to enable broadband connectivity from space. If the megaconstellations come to fruition, this will require more than a thousand launches in the next few years, on top of SpaceX's blistering Starlink launch cadence. We discuss the topic of megaconstellations in this week's Rocket Report.
As always, we welcome reader submissions. If you don't want to miss an issue, please subscribe using the box below (the form will not appear on AMP-enabled versions of the site). Each report will include information on small-, medium-, and heavy-lift rockets as well as a quick look ahead at the next three launches on the calendar.
So, what is SpinLaunch doing now? Ars Technica has mentioned SpinLaunch, the company that literally wants to yeet satellites into space, in previous Rocket Report newsletters. This company enjoyed some success in raising money for its so-crazy-it-just-might-work idea of catapulting rockets and satellites into the sky, a concept SpinLaunch calls "kinetic launch." But SpinLaunch is now making a hard pivot to small satellites, a move that, on its face, seems puzzling after going all-in on kinetic launch and even performing several impressive hardware tests, throwing a projectile to altitudes of up to 30,000 feet. Ars got the scoop, with the company's CEO detailing why and how it plans to build a low-Earth orbit telecommunications constellation with 280 satellites.
Login
